atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares.
The company may also grant the underwriter a 30-day option to purchase up to an additional $8.25 million in shares, it said in a statement after Wednesday's closing bell.
The proceeds from the offering will be used to support atai’s corporate initiatives, including working capital and furthering the clinical development of its product candidates and programs.
Berenberg is serving as the sole bookrunner for the offering.
atai is a clinical-stage biopharmaceutical company developing innovative treatments for mental health disorders.